The semaglutide active pharmaceutical ingredient developed by Space Peptides (Taizhou) Pharmaceutical, which is operating in the Taixing Economic Development Zone in Taixing, Jiangsu province, has completed registration of its Drug Master File with the US Food and Drug Administration.
The company has been focusing on the research and development, production, and innovation of peptide drugs.
Space Peptides (Taizhou) Pharmaceutical. [Photo/WeChat account: txfabu]
The successful obtainment is an authoritative certification of the company's core technical strength and standardized production system, while also enhancing its core competitiveness.
Since the second half of this year, the company's market orders have grown steadily.
The biopharmaceutical industry is one of the highlights in the zone. The zone has scientifically planned the layout of the industry, with a high standard layout of centralized production bases for active pharmaceutical ingredients.
Leveraging its three functional zones—the built-up area, planning area, and expansion area—it has attracted and launched a number of key pharmaceutical R&D projects.